The US Food and Drug Administration has approved Johnson & Johnson’s biweekly dose of Tecvayli blood cancer therapy. The approval allows the therapy to be used at a reduced dose of 1.5 milligrams per kilogram every fortnight in patients who have achieved and maintained a complete or better response for at least six months.